7
Views
2
CrossRef citations to date
0
Altmetric
Review

Clinical application of skin substitutes

, , , &
Pages 345-356 | Published online: 10 Jan 2014

References

  • Boyce ST, Warden GD. Principles and practices for treatment of cutaneous wounds with cultured skin substitutes. Am. J. Surg.183, 445–456 (2002).
  • Boyce ST. Design principles for composition and performance of cultured skin substitutes. Burns27, 523–533 (2001).
  • Lobmann R, Pittasch D, Muhlen I, Lehnert H. Autologous human keratinocytes cultured on membranes composed of benzyl ester of hyaluronic acid for grafting in nonhealing diabetic foot lesions: a pilot study. J. Diabetes Complicat.17, 199–204 (2003).
  • Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J. Cell. Mol. Med.8, 498–508 (2004).
  • Iwami Y, Masuda H, Asahara T. Endothelial progenitor cells: past, state of the art, and future. J. Cell. Mol. Med.8, 488–497 (2004).
  • Manea A, Constantinescu E, Popov D, Raicu M. Changes in oxidative balance in rat pericytes exposed to diabetic conditions. J. Cell. Mol. Med.8, 117–126 (2004).
  • McNulty JM, Kambour MJ, Smith AA. Use of an improved zirconyl hematoxylin stain in the diagnosis of Barrett’s esophagus. J. Cell. Mol. Med.8, 382–387 (2004).
  • Paunescu V, Suciu E, Tatu C et al. Endothelial cells from hematopoietic stem cells are functionally different from those of human umbilical vein. J. Cell. Mol. Med.7, 455–460 (2003).
  • Schiera G, Bono E, Raffa MP et al. Synergistic effects of neurons and astrocytes on the differentiation of brain capillary endothelial cells in culture. J. Cell. Mol. Med.7, 165–170 (2003).
  • Lee KH. Tissue-engineered human living skin substitutes: development and clinical application. Yonsei Med. J.41, 774–779 (2000).
  • Price RD, Das-Gupta V, Leigh IM et al. A comparison of tissue-engineered hyaluronic acid dermal matrices in a human wound model. Tissue Eng.12(10), 2985–2995 (2006).
  • Myers SR, Partha VN, Soranzo C et al. Hyalomatrix: a temporary epidermal barrier, hyaluronan delivery, and neodermis induction system for keratinocyte stem cell therapy. Tissue Eng.13(11), 2733–2741 (2007).
  • Supp DM, Boyce ST. Engineered skin substitutes: practices and potentials. Clin. Dermatol.23(4), 403–412 (2005).
  • Chiu T, Burd A. ‘‘Xenograft’’ dressing in the treatment of burns. Clin. Dermatol.23, 419–423 (2005).
  • Ruparelia BA, GunasheelaSundar K. Anterior and posterior vaginal collapse repairs with porcine skin collagen (Permacol™) implant. Int. Urogynaecol. J.11, FDP33 S45 (2000).
  • Alster TS, West TB. Human-derived and new synthetic injectable materials for soft-tissue augmentation: current status and role in cosmetic surgery. Plast. Reconstr. Surg.105, 2515 (2000).
  • Harper C. Permacol: clinical experience with a new biomaterial. Hosp. Med.62, 90–95 (2001).
  • Belcher HJCR, Zic R. Adverse effect of porcine collagen interposition after trapezoidectomy. A comparative study. J. Hand Surg. (Br.)26B, 159 (2001).
  • Hodde JP, Ernst DM, Hiles MC. An investigation of the long-term bioactivity of endogenous growth factor in OASIS wound matrix. J. Wound Care14(1), 23–25 (2005).
  • Mostow EN, Haraway GD, Dalsing M et al. OASIS venus ulcer. Effectiveness of an extracellular matrix graft (OASIS wound matrix) in the treatment of chronic leg ulcers: a randomized clinical trial study group. J. Vasc. Surg.41(5), 837–843 (2005).
  • Niezgoda JA, Van Gils CC, Frykberg RG et al. Randomized clinical trial comparing OASIS wound matrix to regranex gel for diabetic ulcers. Adv. Skin Wound Care18(5 Pt 1), 258–266 (2005).
  • Onur R, Singla A. Solvent-dehydrated cadaveric dermis: a new allograft for pubovaginal sling surgery. Int. J. Urol.12, 801–805 (2005).
  • Barret JP, Dziewulski P, Ramzy PI et al. Biobrane versus 1% silver sulfadiazine in second-degree pediatric burns. Plast. Reconstr. Surg.105, 62–65 (2000).
  • Mandal A. Paediatric partial-thickness scald burns – is Biobrane the best treatment available? Int. Wound. J.4(1), 15–19 (2007).
  • Arevalo JM, Lorente JA. Skin coverage with Biobrane biomaterial for the treatment of patients with toxic epidermal necrolysis. J. Burn Care Rehabil.20, 406–410 (1999).
  • Weinzweig J, Gottlieb LJ, Krizek TJ. Toxic shock syndrome associated with use of Biobrane in a scald burn victim. Burns20, 180–181 (1994).
  • Kumar RJ, Kimble RM, Boots R et al. Treatment of partial-thickness burns: a prospective, randomized trial using Transcyte. ANZ J. Surg.74, 622–626 (2004).
  • Bello YM, Falabella AF, Eaglstein WH. Tissue-engineered skin, current status in wound healing. Am. J. Clin. Dermatol.2(5), 305–313 (2001).
  • Herman O, Weiss J, Shafir R. Congenital aplasia cutis: nonsurgical treatment with a skin substitute. Plast. Reconstr. Surg.83, 886–868 (1989).
  • Veves A, Falanga V, Armstrong DG et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care24, 290–295 (2001).
  • Brem H, Balledux J, Bloom T et al. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent. Arch. Surg.135(6), 627–634 (2000).
  • Redekop WK, McDonnell J, Verboom P et al. The cost effectiveness of Apligraf® treatment of diabetic foot ulcers. Pharmacoeconomics21(16), 1171–1183 (2003).
  • De SK, Reis ED, Kerstein MD. Wound treatment with human skin equivalent. J. Am. Podiatr. Med. Assoc.92(1), 19–23 (2002).
  • Trent JT. Epidermolysis bullosa: identification and treatment. Adv. Skin Wound Care16(6), 284–290 (2003).
  • Culican SM, Custer PL. Repair of cicatricial ectropion in an infant with harlequin ichthyosis using engineered human skin. Am. J. Ophthalmol.134(3), 442–443 (2002).
  • Ratner D. Skin grafting: from here to there. Dermatol. Clin.16, 75–90 (1998).
  • Ablove R, Howell RM. The physiology and technique of skin grafting. Han. Clin.13, 163–173 (1997).
  • Wheeland RG. The technique and current status of pinch grafting. J. Dermatol. Surg. Oncol.13(8), 873–80 (1987).
  • Akan M, Yildirim S, Misirliolu A et al. An alternative method to minimize pain in the split-thickness skin graft donor site. Plast. Reconstr. Surg.111(7), 2243–2249 (2003).
  • Kilinç H, Sensöz O, Ozdemir R, Unlü RE, Baran C. Which dressing for split-thickness skin graft donor sites? Ann. Plast. Surg.46(4), 409–414 (2001).
  • O’Connor NE, Mulliken JB, Banks-Schlegel S et al. Grafting of burns with cultured epithelium prepared from autologous epidermal cells. Lancet1, 75–78 (1981).
  • Wai-sun Ho. Skin substitutes: an overview. Ann. Coll. Surg. HK6, 102–108 (2002).
  • Harris PA, di Francesco F, Barisoni D et al. Use of hyaluronic acid and cultured autologous keratinocytes and fibroblasts in extensive burns. Lancet353(9146), 35–36 (1999).
  • Harris PA, Leigh IM, Navsaria HA. Pre-confluent keratinocyte grafting: the future for cultured skin replacements? Burns24(7), 591–593 (1998).
  • Munster AM, Weiner SH, Spence RJ. Cultured epidermis for the coverage of massive burn wounds. A single center experience. Ann. Surg.211(6), 676–679 (1990).
  • Hefton JM, Caldwell D, Biozes DG et al. Grafting of skin ulcers with cultured autologous epidermal cells. J. Am. Acad. Dermatol.14(3), 399–405 (1986).
  • Gallico GG, O’Connor NE, Compton CC et al. Cultured epithelial autografts for giant congenital nevi. Plast. Reconstr. Surg.84(1), 1–9 (1989).
  • Compton CC. Current concepts in pediatric burn care: the biology of cultured epithelial autografts: an eight-year study in pediatric burn patients. Eur. J. Pediatr. Surg.2(4), 216–222 (1992).
  • Gobet R, Raghunath M, Altermatt S et al. Efficacy of cultured epithelial autografts in pediatric burns and reconstructive surgery. Surgery121(6), 654–661 (1997).
  • Carsin H, Ainaud P, Le Bever H et al. Cultured epithelial autografts in extensive burn coverage of severely traumatized patients: a five year single-center experience with 30 patients. Burns26(4), 379–387 (2000).
  • Cooper ML, Laxer JA, Hansbrough JF. The cytotoxic effects of commonly used topical antimicrobial agents on human fibroblasts and keratinocytes. J. Trauma31, 775–782 (1991).
  • Damour O, Hua SZ, Lasne F et al. Cytotoxicity evaluation of antiseptics and antibiotics on cultured fibroblasts and keratinocytes. Burns18, 479–485 (1992).
  • Arons J, Wainwright D, Jordon R. The surgical applications and implications of cultured human epidermis: a comprehensive review. Surgery111, 4 (1992).
  • Druecke D, Lamme E, Hermann S et al. Modulation of scar tissue formation using different dermal regeneration templates in the treatment of experimental full-thickness wounds. Wound Repair Regen.12, 518–527 (2004).
  • Boyce ST, Kagan RJ, Yakuboff KP et al. Cultured skin substitutes reduce donor skin harvesting in treatment of excised, full-thickness burns. Ann. Surg.235(2), 269–279 (2002).
  • Boyce ST, Warden GD. Principles and practices for treatment of cutaneous wounds with cultured skin substitutes. Am. J. Surg.183(4), 445–456 (2002).
  • Boyce ST, Kagan RJ, Greenhalgh DG et al. Cultured skin substitutes reduce requirements for harvesting of skin autograft for closure of excised, full-thickness burns. J. Trauma60(4), 821–829 (2006).
  • Boyce ST, Williams ML. Lipid supplemented medium induces lamellar bodies and precursors of barrier lipids in cultured analogues of human skin. J. Invest. Dermatol.101(2), 180–184 (1993).
  • Myers SR, Navsaria HA, Brain AN et al. Epidermal differentiation and dermal changes in healing following treatment of surgical wounds with sheets of cultured allogeneic keratinocytes. J. Clin. Pathol.48(12), 1087–1092 (1995).
  • McKay I, Woodward B, Wood K et al. Reconstruction of human skin from glycerol-preserved allodermis and cultured keratinocyte sheets. Burns20(Suppl. 1), S19–S22 (1994).
  • Supp AP, Wickett RR, Swope VB et al. Incubation of cultured skin substitutes in reduced humidity promotes cornification in vitro and stable engraftment in athymic mice. Wound Repair Regen.7(4), 226–237 (1999).
  • Boyce ST, Supp AP, Swope VB et al. Vitamin C regulates keratinocyte viability, epidermal barrier, and basement membrane in vitro, and reduces wound contraction after grafting of cultured skin substitutes. J. Invest. Dermatol.118(4), 565–572 (2002).
  • Wainwright DJ. Use of an acellular allograft dermal matrix (Alloderm) in the management of full-thickness burns. Burns21, 243–248 (1995).
  • Munster AM, Smith-Meek M, Shalom A. Acellular allograft dermal matrix: immediate or delayed epidermal coverage? Burns27, 150–153 (2001).
  • Sheridan R, Choucair R, Donelan M et al. Acellular allodermis in burns surgery: 1-year results of a pilot trial. J. Burn Care Rehabil.19, 528–530 (1998).
  • Erol OO. Alloderm used in rhinoplasty. Plast. Reconstr. Surg.108(6), 1827–1828 (2001).
  • Gryskiewicz JM, Rohrich RJ, Reagan BJ. The use of alloderm for the correction of nasal contour deformities. Plast. Reconstr. Surg.107(2), 561–570 (2001).
  • Gryskiewicz JM. Alloderm lip augmentation. Plast. Reconstr. Surg.106(4), 953–954 (2000).
  • Rubin PA, Fay AM, Remulla HD et al. Ophthalmic plastic applications of acellular dermal allografts. Ophthalmology106(11), 2091–2097 (1999).
  • Costantino PD, Wolpoe ME, Govindaraj S et al. Human dural replacement with acellular dermis: clinical results and a review of the literature. Head Neck22(8), 765–771 (2000).
  • Warren WL, Medary MB, Dureza CD et al. Dural repair using acellular human dermis: experience with 200 cases: technique assessment. Neurosurgery46(6), 1391–1396 (2000).
  • Yannas IV, Burke JF. Design of an artificial skin. I. Basic design principles. J. Biomed. Mater. Res.14(1), 65–81 (1980).
  • Orgill DP, Straus FH 2nd, Lee RC. The use of collagen–GAG membranes in reconstructive surgery. Ann. NY Acad. Sci.888, 233–248 (1999).
  • Yannas IV, Burke JF, Gordon PL et al. Design of an artificial skin. II. Control of chemical composition. J. Biomed. Mater. Res.14(2), 107–132 (1980).
  • Burke JF, Yannas IV, Quinby WC Jr et al. Successful use of a physiologically acceptable artificial skin in the treatment of extensive burn injury. Ann. Surg.194(4), 413–428 (1981).
  • Grzesiak JJ, Pierschbacher MD, Amodeo MF et al. Enhancement of cell interactions with collagen/glycosaminoglycan matrices by RGD derivatization. Biomaterials18, 1625–1632 (1997).
  • Navsaria HA, Ojeh NO, Moiemen N et al. Reepithelialization of a full-thickness burn from stem cells of hair follicles micrografted into a tissue-engineered dermal template (Integra). Plast. Reconstr. Surg.113(3), 978–981 (2004).
  • Groos N, Guillot M, Zilliox R et al. Use of an artificial dermis (Integra) for the reconstruction of extensive burn scars in children. About 22 grafts. Eur. J. Pediatr. Surg.15, 187–192 (2005).
  • Komorowska-Timek E, Gabriel A, Bennett DC et al. Artificial dermis as an alternative for coverage of complex scalp defects following excision of malignant tumors. Plast. Reconstr. Surg.115, 1010–1017 (2005).
  • Mansbridge J, Liu K, Patch R et al. Three-dimensional fibroblast culture implant for the treatment of diabetic foot ulcers: metabolic activity and therapeutic range. Tissue Eng.4, 403–414 (1998).
  • Hanft JR, Surprenant MS. Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis. J. Foot Ankle Surg.41(5), 291–299 (2002).
  • Allenet B, Parée F, Lebrun T et al. Cost–effectiveness modeling of Dermagraft® for the treatment of diabetic foot ulcers in the French context. Diabetes Metab.26, 125–132 (2000).
  • Kamolz L, Frey M, Meissl G et al. Use of collagen-elastin matrix (Matriderm) for dermal reparation: 12 months experiences in the treatment of severe hand burn injuries. Burns33(Suppl. 1), S19–S19 (2006).
  • Ryssel ÖM, GG. The use of Matriderm® in the setting of early necrectomy and one-stage split-thickness grafting in deep and joint-associated burns. Burns33(Suppl. 1), S7–S8 (2006).
  • Metcalfe AD, Ferguson MW. Tissue engineering of replacement skin: the crossroads of biomaterials, wound healing, embryonic development, stem cells and regeneration. J. R. Soc. Interface4(14), 413–437 (2007).
  • Griffith LG, Swartz MA. Capturing complex 3D tissue physiology in vitro. Nat. Rev. Mol. Cell. Biol.3, 211–224 (2006).
  • Li M, Mondrinos MJ, Gandhi MR et al. Electrospun protein fibers as matrices for tissue engineering. Biomaterials30, 5999–6008 (2005).
  • Luu YK, Kim K, Hsiao BS et al. Development of a nanostructured DNA delivery scaffold via electrospinning of PLGA and PLA–PEG block copolymers. J. Control. Release89(2), 341–353 (2003).
  • Duan X, Sheardown H. Incorporation of cell-adhesion peptides into collagen scaffolds promotes corneal epithelial stratification. J. Biomater. Sci. Polym. Ed.18(6), 701–711 (2007).
  • Li B, Chen J, Wang JH. RGD peptide-conjugated poly(dimethylsiloxane) promotes adhesion, proliferation, and collagen secretion of human fibroblasts. J. Biomed. Mater. Res. A79(4), 989–998 (2006).
  • Fittkau MH, Zilla P, Bezuidenhout D et al. The selective modulation of endothelial cell mobility on RGD peptide containing surfaces by YIGSR peptides. Biomaterials2, 167–174 (2005).
  • Duan X, Sheardown H. Crosslinking of collagen with dendrimers. J. Biomed. Mater. Res. A75(3), 510–518 (2005).
  • Duan X, McLaughlin C, Griffith M, Sheardown H. Biofunctionalization of collagen for improved biological response: scaffolds for corneal tissue engineering. Biomaterials (1), 78–88 (2007).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.